Liver biopsy in assessment of extended criteria donors

Joseph B. Oliver, Praveena Machineni, Advaith Bongu, Trusha Patel, Joseph Nespral, Carie Kadric, Michael J. Goldstein, Harvey Lerner, David Gee, Richard Hillbom, Lloyd Brown, Kenneth Washburn, Baburao Koneru – 21 September 2017 – The safety and liver utilization with prerecovery liver biopsy (PLB) in extended criteria liver donors are unclear. We conducted a retrospective cohort study in 1323 brain death donors (PLB = 496) from 3 organ procurement organizations (OPOs). Outcomes were complications, preempted liver recovery (PLR), and liver transplantation (LT).

Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis

Oliver Krenkel, Tobias Puengel, Olivier Govaere, Ali T. Abdallah, Jana C. Mossanen, Marlene Kohlhepp, Anke Liepelt, Eric Lefebvre, Tom Luedde, Claus Hellerbrand, Ralf Weiskirchen, Thomas Longerich, Ivan G. Costa, Quentin M. Anstee, Christian Trautwein, Frank Tacke – 21 September 2017 – Macrophages are key regulators of liver fibrosis progression and regression in nonalcoholic steatohepatitis (NASH). Liver macrophages comprise resident phagocytes, Kupffer cells, and monocyte‐derived cells, which are recruited through the chemokine receptor C‐C motif chemokine receptor 2 (CCR2).

New pediatric percentiles of liver enzyme serum levels (alanine aminotransferase, aspartate aminotransferase, γ‐glutamyltransferase): Effects of age, sex, body mass index, and pubertal stage

Sarah Bussler, Mandy Vogel, Diana Pietzner, Kristian Harms, Theresa Buzek, Melanie Penke, Norman Händel, Antje Körner, Ulrich Baumann, Wieland Kiess, Gunter Flemming – 19 September 2017 – The present study aims to clarify the effects of sex, age, body mass index (BMI), and puberty on transaminase serum levels in children and adolescents and to provide new age‐ and sex‐related percentiles for alanine aminotransferase (ALT), aspartate aminotransferase (AST), and γ‐glutamyltransferase (GGT). Venous blood and anthropometric data were collected from 4,126 cases.

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

David Wyles, Fred Poordad, Stanley Wang, Laurent Alric, Franco Felizarta, Paul Y. Kwo, Benedict Maliakkal, Kosh Agarwal, Tarek Hassanein, Frank Weilert, Samuel S. Lee, Jens Kort, Sandra S. Lovell, Ran Liu, Chih‐Wei Lin, Tami Pilot‐Matias, Preethi Krishnan, Federico J. Mensa – 19 September 2017 – This study assessed the efficacy and safety of ribavirin‐free coformulated glecaprevir/pibrentasvir (G/P) in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or compensated cirrhosis, a patient population with limited treatment options.

Excellent outcomes in combined liver‐kidney transplantation: Impact of kidney donor profile index and delayed kidney transplantation

Burcin Ekser, Richard S. Mangus, Chandrashekhar A. Kubal, John A. Powelson, Jonathan A. Fridell, William C. Goggins – 19 September 2017 – The positive impact of delayed kidney transplantation (KT) on patient survival for combined liver‐kidney transplantation (CLKT) has already been demonstrated by our group. The purpose of this study is to identify whether the quality of the kidneys (based on kidney donor profile index [KDPI]) or the delayed approach KT contributes to improved patient survival.

Subscribe to